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Abstract 
Background and purpose: Magnetic resonance imaging (MRI) only radiotherapy has, due to superior 
soft tissue contrast of MRI and the possible reduction of systematic uncertainties, grown into a 
promising technique. The purpose of this work is to investigate parts of an MRI only workflow with 
synthetic computed tomography (sCT) images generated from MRI. This was done through 
investigation of treatment planning abilities and patient positioning strategies in a suggested MRI only 
workflow for prostate cancer patients.  
Material and methods: A novel atlas based generation method, The Statistical Decomposition 
Algorithm (SDA), was used for sCT generation. sCT images of six patients were evaluated visually 
and using the DICE similarity index. Treatment plans (Intensity modulated radiation therapy (IMRT) 
and protons) were calculated based on conventional CT and sCT and compared using clinical dose- 
volume histogram (DVH) criteria and gamma evaluation. Patient positioning in the MRI only 
workflow were investigated through two studies, including five patients. The ability to identify 
implanted gold fiducials in MRI was investigated and a MV bone match procedure tested with 
digitally reconstructed radiographs (DRR).   
Results: The image analysis implicated minor problems with the bone surfaces in the generated sCT, 
and some disparities compared to CT were noted. The treatment planning study showed that treatment 
planning on sCT introduced a mean dose difference to PTV of -0.2% to -0.1% compared to CT. 
Gamma analysis showed a mean pass rate close to 100% for IMRT (1%/2mm) and 93% for protons 
(3%/2mm). The fiducial marker identification study showed that the fiducials could be identified, in 
all cases but one. In this case a marker was identified centimeters from the right position. The bone 
match showed differences of 0.7-0.9 mm between match performed with CT-DRRs and sCT-DRRs 
images towards MV images.    
Conclusion: Good agreement in terms of dose accuracy was found when dose distributions were 
compared between sCT and CT treatment plans. The image evaluation indicated disparities in the bone 
surface between sCT and CT, but this had only small effect on the resulting dose distributions for 
photon plans. Patient positioning strategies needs further work and guidelines have to be developed. 
The initial results of this study show a problem with transferring the fiducial marker positioning 
strategies in the conventional workflow to the MRI only workflow. The MV bone match can be 
performed and, although it may not be the preferred procedure for prostate patient, the study showed 
good results and can be usable for other diagnosis.   
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Popular scientific summary in Swedish 
Sedan sent 1800-tal har strålterapi använts för behandling av cancer. 50% av alla cancerpatienter blir 
någon gång behandlade med strålterapi, som är en avancerad teknik med många olika steg för att 
uppnå den slutgiltiga behandlingsplanen. Patienten börjar sin strålbehandlingsresa med att bli 
diagnosticerad och får sin behandling ordinerad. Efter detta startar förberedelserna inför 
strålbehandlingen, vilket är en lång process innan behandlingen kan ges. För att kunna skapa den 
behandling som är ordinerad måste man först ha bilder på patienten där cancern och organ syns. Dessa 
bilder används för att bestämma vart strålningen skall riktas och vilka områden som önskas undvikas. 
Detta görs för att uppnå bästa möjliga behandlingsresultat, samtidigt som biverkningar undviks.  
De bilder man använder till strålbehandlingen fås från en så kallad skiktröntgen. Denna ger 
tredimensionella bilder av patienten där man önskar kunna se cancern samt omkringliggande organ. 
Denna bild skickas till det som kallas för dosplaneringssystemet, vilket är det system där behandlingen 
skapas. Man beräknar här hur mycket strålning som skall ges till cancern, samt justerar så att 
strålningen till omgivande organ inte blir över rekommenderade gränser. Att kunna utföra detta kräver 
att cancern är väl utritad på skiktröntgenbilderna, vilket kräver att man kan se skillnader mellan 
mjukdelarna i kroppen. Tyvärr är en av de stora nackdelarna hos skiktröntgen att det är svårt att skilja 
mellan olika mjukdelar i bilderna. Detta leder till att cancern och organen i patienten kan vara svåra att 
hitta exakt, vilket i sin tur leder till att man riskerar att inte kunna ge den önskade behandlingen. 
För att lösa problemet med de bristfälliga bilderna har forskare riktat in sig mot användningen av en 
annan bildgivande teknik – magnetkameran. Magnetresonans (MR) är en bildgivande teknik som ger 
tredimensionella bilder av patienten utan att använda röntgenstrålning. MR använder starka magnetfält 
för att påverka vattnet i kroppen, vilket ger bilder med mycket god skillnad mellan mjukdelarna i 
kroppen. Dessa bilder är i många fall idealiska för bestämning av cancerns position, vilket i sin tur kan 
leda till bättre behandlingar.  
De system som idag används för att skapa behandlingarna är utvecklade för att passa bilder från 
skiktröntgen och problematik uppstår när bilderna från magnetkameran ska användas. Bilderna från 
magnetkameran passar inte för att utföra de beräkningar av stråldoserna som behövs inför 
behandlingen. För att lösa detta problem har forskare föreslagit att man omvandlar de bilder som 
kommer från magnetkameran till bilder som liknar skiktröntgenbilderna. Man kan på så vis hitta 
cancern och organen på MR bilden, sedan omvandla bilden för att kunna beräkna stråldoserna.   
Precis som alla nya tekniker så medför införandet av ny teknik mycket tester innan slutprodukten kan 
utnyttjas. Detta gäller även för införandet av ny teknik i strålbehandling. Detta arbete föreslår och 
utvärderar en ny strålbehandlingsmetod med MR bilder och jämför denna med den gamla metoden 
med skiktröntgenbilder. Önskvärt var att se om den nya tekniken gav likvärdiga resultat som de gamla 
och utvärdera dess användbarhet. Undersökningar visade att den nya tekniken med MR gav mycket 
lovande resultat och kan potentiellt eliminera osäkerheter som den gamla metoden bidrar med. En ny 
bildteknik utan strålning kan erbjuda många fördelar jämfört med den gamla tekniken, både i 
diagnostiskt syfte och ur behandlingssynpunkt. Vidare undersökningar av metoden förväntas leda till 
införandet av en ny metod för strålbehandling, anpassad till de nuvarande krav som ställs på 
cancerbehandlingar. 	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Abbreviations 
PTV  Planning Target Volume 
OAR Organs at risk 
CT Computed Tomography  
MRI  Magnetic Resonance Imaging 
HUs Hounsfield Units 
sCT Synthetic Computed Tomography 
SDA The Statistical Decomposition Algorithm 
DTA Distance To Agreement 
rCT Deformable Registered Computed Tomography 
IMRT Intensity Modulated Radiation Therapy 
CTV Clinical Target Volume 
AAA Anisotropic Analytical Algorithm 
PBA Pencil Beam Algorithm 
DVH Dose Volume Histogram 
TPS Treatment Planning System  
DRR Digitally Reconstructed Radiograph   
CBCT Cone Beam Computed Tomography 
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1. Introduction 
1.1 Background 
Radiation therapy has been used since late 19th century and has since then developed into a technique 
with great variability, enabling care for many malignant diseases. About 50% of the patients diagnosed 
with cancer are at some point treated with radiation therapy, where the technique stands for 30% of the 
cure of cancer patients worldwide (Cancerfonden, 2015).  The main goal is to treat or control the 
cancer, which in external radiation therapy is done by aiming high energy radiation to an area located 
inside the body called the planning target volume (PTV). In combination with delivering a high 
absorbed dose to the PTV, organs at risk (OAR) and normal tissue should be avoided in order to 
minimize side effects. To accomplish this, high accuracy is needed in all steps of the treatment 
process, often referred to as the radiotherapy chain or the radiotherapy workflow. 
The radiotherapy chain includes all steps from treatment prescription to completed treatment. The CT 
is today the gold standard imaging modality in radiotherapy, and the CT images are used throughout 
the entire radiotherapy chain. The treatment planning system (TPS) requires Hounsfield units (HUs) 
for absorbed dose calculations, which in a conventional workflow is received directly from the CT. 
However, for some diagnoses, such as prostate cancers, a set of magnetic resonance imaging (MRI) is 
preferable for more precise target delineation (Parker et al., 2003). Through co-registration of the MRI 
and CT, using implanted fiducial markers in the prostate, the both modalities can be used for target 
delineation while the CT constitutes the base for treatment planning. When the final treatment plan is 
approved and clinically tested and verified, the patient can begin the treatment. The treatment 
procedure includes several steps, such as positioning, imaging and finally delivery of the prescribed 
treatment. After this, follow up can be done in order to see if and how the tumor has responded to the 
treatment.  
Although the co-registration of MRI and CT for prostate patients is common, the geometric accuracy 
of the method has been questioned (Korsholm et al., 2014). The MRI and CT are unlikely to be 
geometrically comparable, and the co-registration process is therefore associated with uncertainties 
(Lambert et al., 2011). With the ambitions to improve the workflow and minimize the geometrical and 
dosimetrical uncertainties, researchers have been focusing towards the use of solely MRI in 
combination with radiotherapy - called MRI only radiotherapy (Johansson et al., 2011, Siversson et 
al., 2015, Korhonen et al., 2014, Dowling et al., 2012, Andreasen et al., 2015).  
The increased interest of an MRI only workflow in radiotherapy has emerged due to the superior soft 
tissue contrast that MRI provides. It has been shown that an MRI only workflow can reduce the 
systematic uncertainties from 3-4 mm to 2-3 mm when compared to a combined CT/MRI workflow 
for prostate patients (Nyholm et al., 2009). The main contributing factor of the reduced uncertainties 
was exclusion of the co-registration process needed in a combined CT/MRI workflow.  Less inter-
observer differences have also been shown for prostate patients when delineating the target on an MRI 
(Parker et al., 2003) which is a result of the improved soft tissue contrast. The improvement of the soft 
tissue contrast also results in a reduced irradiated rectum volume, since the target volume estimated on 
MRI in general is smaller than on a CT (Debois et al., 1999). The exclusion of the CT in the 
radiotherapy workflow for prostate patients would not only reduce the geometrical uncertainties, but 
also provide reduced costs as the CT can be excluded. This, in combination with the possibility of a 
non-ionizing imaging method, makes the MRI only workflow an alternative that deserves further 
considerations.  
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In an MRI only workflow, the CT would be replaced with an MRI in every step of the chain. Since the 
MRI data doesn’t directly translate into HUs, a conversion is required. In order to accomplish this, the 
concept of a synthetic CT (sCT) has emerged. A synthetic CT image is a substitute for the CT, 
generated from MRIs through various methods. The idea of an MRI radiotherapy workflow has 
interested several groups of researchers, and encouraged them to develop different types of sCT 
generation methods. Some groups suggest generation methods where individual voxels are classified 
into tissue types (Johansson et al., 2011). Other groups have investigated a method where the sCT 
generation relies upon a database of several tissue types, originated from multi template patient 
materials (Siversson et al., 2015). Regardless of the sCT generation method, the aim is to produce a 
substitute CT image from an MRI and thus enabling an MRI only workflow.  
From selection of generation method to positioning strategy, there are various ways to go and several 
options to choose from. Regardless of the choice of strategy, the reliability of the sCT is essential, as 
both treatment planning and patient positioning is dependent on the result.  
1.2 Aim 
This thesis focuses on parts of an MRI only radiotherapy chain where synthetic CT images can replace 
the gold standard CT in the workflow for prostate cancer patients.     
The aims were investigated with an MRI only workflow as foundation – and compared to a combined 
CT/MR workflow. The following specific aims were formed for this thesis: 
• Investigate the image similarities of sCT and CT images and detect where, if any, 
dissimilarities can be found.  
• Create treatment plans of various natures and compare absorbed dose calculation results 
between sCT and CT.  
• Investigate patient positioning strategies in an MRI only workflow.  
Advantages, challenges and future perspectives with a potential MRI only workflow will be discussed.  
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2. Theory 
2.1 sCT generation methods  
2.1.1 General 
The generation methods can be divided into two major groups – Voxel based and atlas based 
generation methods. However, some methods are a combination of the two major groups.  
Johansson et al. has developed a voxel based generation method that uses a trained set of matched MR 
and CT data to predict a sCT. They uses a Gaussian mixture regression model that makes use of three 
different MR sequences, a T2 weighted spin echo and two dual echo ultra short echo time sequences. 
The model links the voxel values in images from the MR sequences to the CT voxel values (Johansson 
et al., 2011). Dowling et al. have instead of the voxel approach chosen an atlas based generation 
method, developed for prostate patients. In order to generate a sCT they make use of a multi-modality 
atlas of registered MRIs and CTs, and register the MRIs to the patients MRI scan. The MRI sequences 
in this work was two T2 weighted scans and one T2* scan. Through transformation and deformations 
of the corresponding CT atlas, a sCT can be created according to the patient anatomy (Dowling et al., 
2012). In the current article, the sCT is referred to as a pseudo CT (pCT), which is a common name for 
the generated CT substitute.  
The atlas and voxel based methods have different advantages, but are also associated with drawbacks. 
The voxel based methods have the drawback that exotic pulse sequences often is required for 
discrimination between bone and air (Jonsson et al., 2013), while the atlas based methods relies upon a 
direct database which can be troublesome for patients with atypical anatomy (Dowling et al., 2012).  
Korhonen et al. suggests in their work a dual model HU conversion method. The method converts 
MRI intensity values into HUs for prostate cancer patients. The pCT is created from a combination of 
T1/T2* sequences and CT data (Korhonen et al., 2014). This technique differs from the atlas and 
voxel based methods in the way that they do not directly make use of the voxel values or of an atlas 
database. This is also the case for Andreasen et al. which technique creates pCTs from T1-weighted 
scans using a database of patches. The patch is defined as a cube with m voxel size side length in an 
MRI (Andreasen et al., 2015). This technique is in some manor an atlas based method, but with a 
unique procedure that replaces the patient atlas with patches.     
The sCT images investigated in this thesis were generated using the Statistical Decomposition 
Algorithm (SDA), which is a novel method for generating sCT images from MRI-based material. The 
SDA is presented in a parallel work accepted for publication (Siversson et al., 2015). The method is 
soon to be released as a clinical product developed by Spectronic Medical AB in collaboration with 
researchers from Lund University. This product will also be used in the Swedish project Gentle 
Radiotherapy, which is an effort to incorporate MRI in the radiotherapy chain. 
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2.1.2 The Statistical Decomposition Algorithm 
The automated SDA method is an atlas- based method that makes use of a multi-template assisted 
classification method. The MRI is automatically decomposed into several tissue types, whereupon the 
tissue types are statistically analyzed. The statistical analysis finds the most probable CT 
representation for the particular individual, depending on several features such as shape- and textures 
of the tissue types. The SDA uses a multi template material, consisting of both MRI and CT from 
various patients, to create the most likely CT representation for each tissue type. Finally, the sCT is 
generated through fusion of the individual tissue types. Figure 2.1 illustrates the SDA method in a 
simplified manner from the point of incoming MRI patient material, to final representation of the sCT.  
 
 
  
Figure 2.1 The SDA method illustrated from starting point to final generation of the sCT. The 
incoming MRI patient material is decomposed into tissue-types and compared to the multi-
template material consisting of several patients. The most probable CT representation is 
found in the atlas for each tissue-type and the sCT is generated through fusion of the 
individual tissue-types.  
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2.2 The DICE similarity index 
The original version of the DICE similarity index (Dice, 1945) was initially developed for the field of 
ecology. At the time there was no good measure to express how two different species were associated 
in nature, and so the DICE similarity index was presented. The article suggests an equation where the 
resulting index ranges from 0 to 1, where 0 indicates no association and 1 shows complete association 
of the two species examined in all samples. Although the original paper was directed to the field of 
ecology, the DICE similarity index is also a common method in the field of image processing. In 
recent works, the index is used for evaluation of generated sCT images (Jonsson et al., 2015, 
Andreasen et al., 2015). The DICE similarity index will in this work be used according to the 
following equation:  
                       𝐷 = !∙!!!! ∙ 100                   (2.1) 
Where O is the number of pixels that agrees in the images A and B, called overlapping pixels, and 
variables a and b corresponds to the number of pixels in image A and B respectively. If image A and 
B are identical, the number of pixels in each of the images is the same. This leads to that if the number 
of pixels that are overlapping in the two images are multiplied with two, this should correspond to the 
summation of a and b. If there is any dissimilarity, this leads to a smaller number of overlapping 
pixels, than expected when the pictures totally agree. Finally, in order to get a measure of the 
similarity of the images, the multiplication of the overlapping pixels are divided with the summation 
of a and b. This multiplied with 100, gives the measure in percent of pixels that agrees in the images. 
This is what is referred to as the DICE similarity index, D, demonstrated with two examples in Figure 
2.2.  
 
Figure 2.2 The figure demonstrates the idea behind the DICE index used in this work. If A and B are compared to 
each other, differences can be detected if present. If A and B were identical, the sum of the pixels in A and B should 
correspond to the number of pixels in O multiplied by 2. To the left we can see examples were the DICE similarity 
index would not be equal to 100%, due to dissimilarities in A and B. The summation of pixels in A and B will be larger 
than twice the number of the pixels in O, leading to D<100%. To the right we have an example were A and B exactly 
agrees, which leads to D=100%.  
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2.3 Gamma evaluation  
The gamma evaluation method is used for comparison of dose distributions and was proposed by Low 
et al, 1998 for comparison of two-dimensional dose distributions. Low presented a method for 
comparison between measured and calculated dose distributions by the use of dose differences and 
distance to agreements (DTA). In the original version, the comparison is made between a measured 
point, 𝒓!, and a calculated point, 𝒓!, in the two compared dose distributions. In this thesis, these will 
be replaced with points in two calculated dose matrices, one reference point, 𝒓!, in the reference dose 
distribution and one evaluated point, 𝒓!, in the evaluated dose distribution. Low uses the measured 
dose distribution as a reference and the calculated as evaluated distribution, hence 𝒓! replaces 𝒓! and 𝒓! replaces 𝒓!.  
The method uses acceptance criteria, the dose difference criterion  ∆𝐷!, and the DTA criterion  ∆𝑑!. 
These two criteria can be visualized as an ellipsoid where the surface represents the acceptance 
criteria; this is illustrated in Figure 2.3. The equation of the ellipsoid is 
       1 = !! 𝒓!,𝒓∆!!! + !! 𝒓!,𝒓∆!!!                   (2.2) 
The right hand side of equation 2.1 can be used to define the gamma index. The gamma index is 
defined as: 
   𝛾 𝒓! = 𝑚𝑖𝑛 Γ(𝒓! , 𝒓!)   ∀(𝒓!)                  (2.3) 
Where 
   Γ 𝒓! , 𝒓! = !!(𝒓!,𝒓!)∆!!! + !!(𝒓!,𝒓!)∆!!!                   (2.4) 
The spatial difference between the reference and the evaluated point is represented by 𝑟(𝒓! , 𝒓!)  and 𝛿(𝒓! , 𝒓!) represents the absorbed dose differences between the reference and evaluated point. The 
gamma calculation is made for a single point in the reference distribution against all reference points. 
If any point in the evaluated matrix meets the selected criterion the reference point passes, and the 
evaluated point can be seen as located inside of the ellipse. If none of the evaluated points fulfill the 
chosen criterion, the reference point fails. The pass-fail criteria are defined as: 
  𝛾(𝒓!) ≤ 1 Point passes                                 (2.5) 
                                               𝛾(𝒓!) > 1 Point fails                                                                          (2.6) 
If several reference points are evaluated, the gamma pass rate can be defined as the ratio between the 
number of points that passes the gamma calculation and the total number of points evaluated. The 
gamma evaluation is applicable in 1-3 spatial dimensions.  
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Figure 2.3 A geometrical representation of the gamma evaluation method for a 2D dose distribution, with combined 
criterions for dose differences and DTA. The figure is drawn based on the figure in the original paper on the gamma 
evaluation method (Low et al., 1998). The x- and y-axes represents the spatial plane and the 𝜹 axis represents the dose 
differences between the measured and calculated absorbed doses.  
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3. Material and Methods 
3.1 The MRI only workflow 
As a foundation for this thesis, an MRI only workflow using sCT was suggested. The workflow covers 
the steps from the point where the patients are positioned prior to imaging in the treatment fixation, to 
follow up after completed treatment. The MRI only workflow was designed with the conventional 
workflow for prostate cancer patients in mind and within every step where a CT is used an MRI or 
sCT was inserted. The main parts were the sCT takes part is in the target and risk organ delineation, 
generation of the sCT and the following treatment planning. After this the plan is verified and tested, 
according to the routines at the particular treatment clinic, and finally the patients are ready for 
positioning prior to treatment. The positioning includes several steps, and depending on the technique 
available, the positioning procedure can differ. In the suggested workflow, the positioning was divided 
into soft tissue and bone or fiducial markers. Positioning with fiducial markers is a well-established 
strategy for prostate patients. When this is not possible, a bone and soft tissue match can be performed. 
The use of solely soft tissue match would preferably be performed with an MRI combination were the 
patients can be positioned according to a nearby MRI (Karlsson et al., 2009) or with the use of an 
integrated MRI Linear accelerator (Lagendijk et al., 2014). After positioning the patients can be 
treated according to prescription and after completed treatment, follow up can be achieved if required. 
With MRI, the possibility of follow up during and after treatment is enabled without excess radiation.   
 
Figure 3.1 Suggested MRI only workflow. In this work the CBCT was referred to as a bone and soft tissue matching 
procedure. The bones were considered as the matching object in CBCT and the soft tissue as a guide to the match. 
Rectum and bladder should have the same degree of filling as when the treatment planning images was acquired, in 
order to deliver the treatment as planned. A solely soft tissue match would preferably require soft tissue visualization, 
which could be done with an MRI according to the right hand side of the workflow. The CBCT and kV/MV match 
could be used as a solely bone match procedure.   
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3.2 Patient material 
Datasets with images of 11 patients, treated for prostate cancer, were received from Umeå University 
and included in this study. The patients’ primary diagnosis was not considered when target and risk 
organs were delineated, but instead each patient was considered as having strictly the prostate as the 
CTV.  
Six of the patients were included in the image analysis and the treatment planning study and the 
remaining five patients were included in the positioning study. The division into two groups was 
necessary, since all patients didn’t have the image material needed for both studies. The time limit of 
the thesis, and limited patient material, restricted the use of larger patient selections for each study.  
3.3 Image material 
Prior to treatment prescription, each patient included in the study had an MR and a CT image session. 
The MRI was acquired with an Espree 1,5T scanner (Siemens Healthcare, Erlangen, Germany), using 
a T2 weighted 3D turbo inversion recovery sequence (SPACE). This was acquired with repetition time 
1500 ms, echo time 208 ms and a flip angle of 150°. The image matrix was 384×384×120 voxels 
with the voxel size 1,1×1,1×1,7 mm, and the field of view was set to surround the outer body contour 
for each individual patient case. The CT images was acquired using a SOMATOM Emotion 6 scanner 
(Siemens Healthcare, Erlangen, Germany), with in plane resolution ranging from 0.86 to 0.96 mm 
with slice thickness 2.5  mm.  
The patients were positioned with the same strategy prior to both MR and CT, with fixation of the feet 
and with knee support. The MR images were acquired directly after the CT, in order to minimize the 
effect of organ movements and deformations (e.g. filling of the rectum and bladder) between imaging 
sessions. The patients had no food restrictions prior the imaging sessions. The rectum diameter was 
controlled on the CT overview image and the imaging proceeded if a rectum diameter of less than four 
centimeter was measured. If not, the patient was asked to visit the toilet before the imaging proceeded.  
The MRI was used for generation of the sCT according to the SDA based method developed by 
Spectronic Medical AB, who also provided the sCT images. The resulting sCT images were of the 
same resolution and had the same frame of reference as the MRI. In order to evaluate the sCT, without 
introducing errors originating from repositioning between MRI and CT, an additional set of CT 
images was generated, called registered CT (rCT). The concept of an rCT image comparison have 
been suggested in a parallel work accepted for publication (Siversson et al., 2015). The rCT images 
were created by Spectronic Medical AB, using deformable registration and the elastic toolbox, in 
which each CT was registered to its corresponding MRI. This enables the sCT to be compared to the 
CT without including the errors introduced by the repositioning and excludes the effect of geometrical 
distortions. The rCT can be compared to the CT in order to evaluate the errors introduced by the 
multiple imaging sessions required in a combined workflow.  
The patient positioning study required images from the patient positioning sessions obtained during 
treatment. The available images from the treatment sessions at Umeå were orthogonal MV images, 
which were received along with MR, CT and MR images for fiducial marker identification.  
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Figure 3.2 Images received from Umeå university hospital, MRI and CT, and from Spectronic Medical AB, rCT and 
sCT. The images displayed belong to patient case 1, and the other patient cases contained the same image information.  
3.4 Image evaluation 
The hypothesis was that differences were expected to be found in the bones in the images, particularly 
at the bone surfaces. This is expected since the sCT is created from an MRI were no bones can be 
seen. For this reason it was the bony structures that were chosen as a measure of the agreement of the 
images. The higher attenuation in bones, compared to muscle and fat, can result in a larger error in 
dose distribution if the bones are positioned differently.  
The images were evaluated with the DICE similarity index. The evaluation gives a measure of the 
agreement (i.e. similarity) between the generated sCT and the original CT. For the comparison, the 
rCT worked as reference and was compared to the sCT and the CT. MATLAB (The MathWorks inc.)  
was used for the evaluation. A threshold of 200 HU was set to identify and segment the bones in the 
images, whereas those pixels identified as bones were set to 1 and otherwise 0. The pixels were 
summarized in each of the three image matrices and the number of overlapping pixels in sCT/rCT and 
CT/rCT was calculated. Finally equation 2.1 was used for calculation of the DICE similarity index. 
The DICE similarity index was expressed in percent, where 100% corresponded to a perfect agreement 
between the binary images. An index below 100% pictured a difference. Since the index merely gave a 
number of the agreement between the images, further analysis was needed to detect where the 
potential differences appear. The threshold images were overlaid in MATLAB and the differences 
were colored in order to visualize the in dissimilarities.  
In order to make a fair comparison, concentrated to the bone surface, the cavities arising from the 
threshold were filled prior to the DICE calculation. The DICE index was calculated in 20 slices 
surrounding the PTV and the mean DICE value were calculated for each patient. This was done in 
order to minimize the effect of the threshold and slice selection. 
3.5 Treatment planning 
Cancer treatment with external radiation therapy is a technique that has a large variety of modalities 
available. RapidArc and IMRT are modalities commonly used for treatment of prostate cancer, and 
IMRT was one of the modalities chosen for evaluation in this work. RapidArc had already been 
showing promising results in a parallel work (Siversson et al., 2015), and is for this reason excluded 
from this work. The use of other modalities than RapidArc was done to test the usability of the sCT 
concept with different treatment techniques, in order to evaluate the MRI only chain with a wider 
perspective. Different techniques may be differently sensitive to insecurities in HUs, and therefore 
IMRT was investigated. The hypothesis was that IMRT could be more sensitive to density differences 
than RapidArc. A difference in density along the path of the radiation fields should have a greater 
influence on the dose distribution from IMRT compared to RapidArc. RapidArc radiates in all angles 
around the patient, and the density effect should therefore be of less impact for this technique.   
Proton therapy is another modality that can be used for treatment of prostate cancer. The Scandinavian 
Proton Therapy Center Skandionkliniken is scheduled to open for treatments in summer 2015. Based 
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on the increased availability of proton treatment, both nationally and internationally, this modality was 
also included in the evaluation of sCT for treatment planning. 
3.5.1 IMRT treatment planning 
Two five field sliding-window IMRT treatment plans, with energies 6MV and 10 MV respectively, 
was generated for each patient using the Eclipse treatment planning system (Varian Medical systems, 
Palo Alto, CA). The prostate and OARs were automatically segmented using the MriPlanner software 
(Spectronic Medical AB, Sweden) on the MRI, according to the idea of an MRI only workflow. The 
structures were copied and transferred to the image sets used. The PTV was created through expansion 
of the clinical target volume (CTV) with 7 mm in all directions.    
The prescribed dose was 78 Gy with 2 Gy per fraction. All treatment plans was created with the gantry 
positioned at 40, 110, 180, 250 and 320 degrees. The plans were optimized using the Dose volume 
optimizer, version 10.0.28, and a final dose calculation was made with the anisotropic analytical 
algorithm (AAA) version 10.0.28. All plans fulfilled the dose volume constraints of the conventional 
arm of the Swedish multicenter Phase III study of HYPO-fractionated Radiotherapy of intermediate 
risk localized Prostate Cancer (HYPO-RT-PC). For complete dose volume constraints, see Table 3.1. 
The rCT was used as image material for the initial treatment planning and the final treatment plan was 
recalculated on the sCT and the CT. The rCT plans created were normalized to 100% in PTV mean 
dose before recalculation on sCT and CT. The plans transferred to the sCT and CT were identical to 
the plan created on the rCT, with same field setup, and contained the same number of monitor units for 
each field after final dose calculation. The alignment of the five fields were found to be adequate to 
meet the dose volume constraints, and the use of five field IMRT for prostate treatment have been 
described in the work of others (Tomiyama et al., 2014). In Figure 3.3 the final dose distributions for 
patient case 1 is illustrated.  
Table 3.1 Dose volume constraints used for the IMRT treatment planning study. The constraint was used as 
references when creating the treatment plans, and all plans was optimized to fulfill the constraints. The constraints, 
presented in both percent and Gy, are used in the conventional arm of the Swedish multicenter Phase III study of 
HYPO-fractionated Radiotherapy of intermediate risk localized Prostate Cancer (HYPO-RT-PC).  
Priority Volume Dose volume constraint 
1 CTV Dmin>95% Dmin>74Gy 
2 PTV V95%>95% V74Gy>95% 
3 Rectum V90%<15% V70Gy<15% 
4 PTV D99%>90% D99%>70Gy 
5 Rectum V75%<35% V59Gy<35% 
6 Femoral heads 
Dmax<70% 
Dmax<55Gy 
7 Rectum V65%<45% V51Gy<45% 
17	  
	  
8 Body Dmax<105% Dmax<82Gy 
 
 
Figure 3.3 Illustration of dose distributions for patient case 1, planned with five 6MV IMRT fields in Eclipse (Varian 
Medical systems, Palo Alto, CA). The illustration pictures the dose distribution for the created rCT plan and the dose 
distribution obtained through recalculation on the CT and sCT images respectively. 
3.5.2 Proton treatment planning  
A spot scanning proton treatment plan was generated for each patient, using the Eclipse treatment 
planning system (Varian Medical systems, Palo Alto, CA) available at Skandionkliniken. The same 
structures as for the IMRT treatment planning study was used, although with other CTV to PTV 
margins. The CTV was expanded with 7 mm in all directions to create the PTV; except in the lateral 
direction were the margins was set to 12 mm.  The lateral expansion has been described by Meyer et 
al. which also uses a similar CTV to PTV expansion in the remaining directions. The margins were 
used in order to account for proximal and distal range uncertainties and potential setup and motion 
errors (Meyer et al., 2010). The prescribed dose was 78 Gy with 2 Gy per fraction, with a RBE 
correction factor of  1.1. Given this, a dose prescription of 70.909 Gy with 1.818 Gy/fraction was 
specified in the TPS. The PTV margins and the RBE correction factor was consistent with the 
recommendations from the International Commission on Radiation Units and Measurements No.78 
report (ICRU, 2007).  
All treatment plans consisted of two opposed lateral beams, with the gantry angled at 90 and 270 
degrees, optimized to deliver a uniform dose to PTV using single field optimization. The final dose 
calculation was made with a pencil beam algorithm (PBA, Proton Convolution Superposition 
v13.0.28).  The same approach as for the IMRT treatment planning was used; creating the initial plan 
on the rCT with a normalization of 100% in PTV mean dose, following recalculation on the sCT and 
CT images. The created proton plans were optimized to fulfill the same criteria as the IMRT plans, 
given in Table 3.1. In Figure 3.4 the final dose distributions for patient case 1 is illustrated. 
 
Figure 3.4 Illustration of dose distributions for patient case 1, with a two field proton plan in Eclipse (Varian Medical 
systems, Palo Alto, CA). The illustration pictures the dose distribution for the created rCT plan and the dose 
distribution obtained through recalculation on the CT and sCT images respectively.   
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3.5.3 Dose volume histogram evaluation 
For the dose volume histogram (DVH) evaluation process, the rCT was used as the reference. The sCT 
and the CT plan were compared to the rCT plan, analyzing the mean doses to PTV, CTV, bladder, 
rectum, femoral heads and the body. Further, the DVH points mentioned in the HYPO-study were also 
analyzed, see Table 3.1. For extraction of the points of interest, the plan evaluation tool in Eclipse was 
used in combination with an in-house developed program, based on the Eclipse Scripting API, for 
parameter extraction. 
Differences in absorbed dose between sCT/rCT and CT/rCT plans were determined for each patient, 
and the mean value and standard deviation (1 s.d.) was calculated for all patients. Due to differences in 
field of view in the slice direction between the CT and rCT, the Body mean value was excluded from 
the CT result.  
3.5.4 Gamma analysis 
In addition to the DVH analysis, a gamma analysis was made for each individual patient comparing 
the sCT to the rCT dose distribution and the CT to the rCT dose distribution. As described in the 
theory section (see section 2.3) this gamma analysis was made between two calculated dose matrices. 
The rCT dose matrix was set as a reference and the CT and sCT dose matrices were used as evaluation 
distributions.  
The gamma analysis was made with an in-house developed MATLAB program. A 2D gamma map 
was calculated for the isocenter slice, taking into account the nearest slices of the evaluated 
distributions (i.e. evaluation in all three spatial dimensions). The gamma pass rate was determined for 
each patient case, both for the sCT/rCT and the CT/rCT comparison. The result for the individual 
patient evaluation was presented as a bar chart, comparing the sCT/rCT with the CT/rCT analysis 
expressed as the gamma pass rate. Gamma criteria of 1%/2mm for IMRT and 3%/2mm for protons, 
local dose deviation, were used. The use of these particular gamma criterions was intended to test the 
limitations of the used generation method, and discover any possible insufficiencies of the method. 
The use of a more common criterion, such as 3%/3mm for IMRT, would not give any, or very limited, 
additional information beyond the DVH-analysis, this since the sCT were expected to be similar to the 
rCT. All dose criteria express local dose difference.   
3.6 Positioning study  
A positioning study was conducted to investigate the possibilities of patients positioning in an MRI 
only workflow. Through examination of the image material available in an MRI only workflow 
compared to the combined CT/MR workflow, difficulties and possibilities with MRI only positioning 
strategies was described.  A MV bone match procedure was tested and a fiducial marker identification 
study performed.  
The positioning of the patient is a step that important in order to deliver the prescribed treatment. If the 
patient is incorrect positioned the purpose of the treatment may be lost, since the treatment is 
constructed with regard to a specific positioning of the patient. In a combined CT/MR workflow for 
prostate patients, a CT image or a digitally reconstructed radiograph (DRR) works as a reference 
image for positioning of the patient during the treatment session. This image is matched with an image 
acquired during the treatment session, which commonly is a cone beam CT (CBCT) image or a pair of 
mega voltage (MV) or kilo voltage (kV) images. The image match for prostate cancer patients is made 
either with bones and soft tissue as reference, or with fiducial markers. The CBCT match is performed 
on bones with the soft tissues as guide, and the CBCT is therefore referred to as a bone and soft tissue 
match procedure. From the match, a calculated couch travel is acquired, according to which a 
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movement of the couch can be performed in order to transfer the patient to the right treatment position. 
In the suggested MRI only workflow the positioning strategies can proceed in the same manner as in 
the conventional workflow; with the CT replaced with an MRI, sCT or DRR reconstructed from the 
sCT.  
3.6.1 Bone match  
In an MRI only workflow the CT-DRR must be replaced with a sCT-DRR when considering a bone 
match with MV or kV images. This is a matching procedure that can be used for prostate cancer 
patients with no possibility of fiducial markers (e.g. radical prostatectomy), or the cases where the 
prostate glands are a part of the CTV. CBCT match with bones is also a common technique for these 
patients, but not always available. In order to test a bone match procedure, the image material 
consisting of CT, sCT and MV images were imported into Eclipse. The CT and sCT were rigidly 
registered to each other, using the bones to achieve the best possible agreement between the images. 
The two images were placed in the same coordinate system; creating plans with two orthogonal fields, 
with identical isocenters. This enabled a comparison of the displacement arising from matching the 
CT-DRR and sCT-DRR against the MV images. If the bones in the CT-DRR and sCT-DRR were 
identical, equal displacements was expected.  
DRRs were created for each field and plan, and the MV images were imported into Aria. The Eclipse 
Offline review tool was used to test the matching procedure. The images were manually matched to 
achieve the best possible bone match between the MV images and the CT-DRR and sCT-DRR 
respectively. The displacement in lateral, longitudinal and vertical direction was noted for both sCT 
and CT. These results were used for comparison of the two techniques, investigating if an MRI only 
workflow could position the patients with the same positions as the conventional workflow.  
3.6.2 Fiducial marker identification 
The fiducial markers were not possible to detect in the T2 weighted images used for sCT generation. 
This is a problem that the combined MR/CT workflow also has, and in order to detect the markers, an 
extra MRI set is used for identification. In a combined workflow the identification can be performed 
with the CT as a reference were the markers should appear. In an MRI only workflow this is not 
possible, and the extra MRI set must be used on its own. Since the identification of the markers not 
always is self-evident, a study was carried out to see with which precision the markers could be 
detected.  
The MR set used for identification in the combined workflow (LAVA-flex) was imported into the 
Eclipse TPS and the contouring tool was used for identification and marking of the fiducial markers. 
One of the five patients was excluded due to a change in the MR protocol used, resulting in a different 
MRI sequence for identification of the fiducial markers for this patient. Six observers performed 
identification of the markers, independently of each other, for each of the remaining four patients. The 
observers had different experience with fiducial marker identification, but with enough experience to 
manage the task.  Each observer was instructed to mark the right-most marker as the first, the left-most 
as the second and the marker placed most centered as the third. The marker position was noted for 
each observer in x-, y- and z-direction, and the result compared within each patient. Each observer was 
also instructed to grade the degree of confidence, from one to five, which the markers were placed 
with. The confidence level was dependent on how the observer experienced the identification and the 
ability to send the patient further to treatment. Only the LAVA-flex set was available for marking, and 
it was not permitted to use neither the CT nor the other observers’ markers as help. In Table 3.2 the 
confidence grading is described in more detail.  
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Table 3.2 The different levels of confidence used in the fiducial marker study ranging from one to five. The levels were 
set with the MRI only workflow in mind and the possibility to pass the patient on further down the workflow as the 
goal.  
Level of confidence Explanation 
1 Very doubtful Identification not possible. 
2 Doubtful 
 
Identification deficient; 
Patient could not be passed on. 
3 Undetermined 
 
Identification possible;  
Hesitant decision if the patient could be passed on. 
4 Confident 
 
Identification confident;  
Patient can safely be passes on, although the images 
had more to be desired. 
5 Very confident Identification convincing.   
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4. Results 
4.1 Image evaluation 
The image evaluation consisted of a visual evaluation and a DICE calculation. In Figure 4.1 the 
visualization and DICE calculation for five slices for patient case 2 and 5 are displayed. Patient case 2 
had the lowest mean DICE value and patient case 5 had the highest mean DICE value, when 
considering both sCT/rCT and CT/rCT comparisons. The DICE value was in general lower for the 
more cranial slices, and the sCT/rCT comparison showed a lower DICE value than the CT/rCT 
comparison. The mean DICE value for all patients was 87.8% for the sCT/rCT comparison and 92.8% 
for the CT/rCT comparison. The most visible differences were seen in the bone edges, at the higher 
parts of femur near the hip joint, and at narrow connective parts of the bones found in the cranial 
slices. For complete information for each patient case and slice, see Appendix VI and Appendix VII.    
 
Figure 4.1 The DICE value in five slices for two patients is presented in the above image. The slices ranges from 20 to 
40, where 20 is the slice located closest to the feet’s and slice 40 located closest to the head of the patients. Pink and 
green color corresponds to pixels that did not agree in the images, green presents pixels belonging to rCT and the pink 
the sCT or CT. White areas corresponds to pixels that agrees in the compared images, called overlapping pixels.   
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4.2 Treatment planning 
4.2.1 IMRT treatment planning  
Figure 4.2 and Figure 4.3 shows the mean differences in absorbed dose when CT and sCT was 
compared to the rCT for the six patients evaluated. For the comparison, point doses were evaluated 
according to the constraints presented in section 3.5.3. The zero mark represents perfect match 
between the dose/volume points compared, and any deviation from the line pictures a difference. For 
complete information of each patient case see Appendix I and Appendix II.  
The result shows a small deviation between sCT and rCT for all DVH points evaluated. The deviations 
were below 1%, with a standard deviation ranging between 0.0% to 1.4% for all points and both 
energies evaluated. The CT/rCT comparison shows larger deviations in general, where the largest 
deviations can be seen for the bladder and rectum DVH points. The PTV DVH points show for both 
comparisons high agreement, and is the structure that has the smallest deviations for both 
comparisons.  This result is consistent for both energies evaluated, and in general, a similar result can 
be seen for all DVH points evaluated.  The standard deviation is larger for the CT/rCT comparison, 
where a standard deviation of approximately 4-5% can be seen for the irradiated rectum volume.  
 
Figure 4.2 The bar chart presents the differences in absolute doses (presented in %) between sCT/r CT, red bars, and 
CT/rCT, blue bars, for specific organ doses. The evaluation was made for 6MV IMRT. The organs doses are divided 
into 14 groups, presented on the x-axis, were each group consists of the result from the sCT/rCT and CT/rCT 
comparison. Each group is presented with its individual standard deviation as error bars (1 s.d.).   
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Figure 4.3 The bar chart presents the differences in absolute doses (presented in %) between sCT/r CT, red bars, and 
CT/rCT, blue bars, for specific organ doses. The evaluation was made for 10MV IMRT. The organs doses are divided 
into 14 groups, presented on the x-axis, were each group consists of the result from the sCT/rCT and CT/rCT 
comparison. Each group is presented with its individual standard deviation as error bars (1 s.d.).   
 
The gamma analysis was carried out for each patient case and the resulting gamma map for the 
isocenter slice is presented in Figure 4.4 and Figure 4.5 for 6 and 10 MV respectively. In this study a 
five field IMRT setup was used for each patient, and the typical field edges of the five IMRT-fields 
can be seen as streaks of light blue color in the gamma analysis visualization. This is a result of the 
dose-calculation on the different images, in which difference can be seen in the field edges.  
 
Figure 4.4 The figure illustrates the gamma analysis in 3D for the IMRT 6MV treatment planning. The isocenter slice 
from the evaluation between sCT/rCT and CT/rCT is shown where the top row presents the sCT/rCT comparison 
and the bottom row shows the CT/rCT comparison. Points with a value ≤ 1 passes the gamma criterion. Beneath each 
patient case, the gamma pass rate is presented in percent, and the mean value is presented below each row of patients. 
The gamma criterion used is 1%/2mm.  
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Figure 4.5 The figure illustrates the gamma analysis in 3D for the IMRT 10MV treatment planning. The isocenter 
slice from the evaluation between sCT/rCT and CT/rCT is shown where the top row presents the sCT/rCT 
comparison and the bottom row shows the CT/rCT comparison. Points with a value ≤ 1 passes the gamma criterion. 
Beneath each patient case, the gamma pass rate is presented in percent, and the mean value is presented below each 
row of patients. The gamma criterion used is 1%/2mm. 
4.2.2 Proton treatment planning  
Figure 4.6 shows the DVH evaluation bar chart resulting from the dose point evaluation of the proton 
treatment plans for the six patients included in the treatment planning study. The comparison was 
made in the same manner as the IMRT DVH evaluation and the bar chart presented below presents the 
mean differences in absorbed dose when CT and sCT was compared to rCT.   
Mean absorbed dose differences for the proton CT/rCT comparison was −0.3 ± 0.2% (1 s.d.) for 
PTV, −0.1 ± 0.1% (1 s.d.) for CTV, 3.0 ± 6.6% (1 s.d.) for the bladder and −1.1 ± 4.0% (1 s.d.) for 
rectum. The corresponding differences in mean absorbed doses for the sCT/rCT comparison 
were  −0.1 ± 0.2% − 0.1 ± 0.1%, −0.0 ± 0.6% and −0.3 ± 0.6% (1 s.d.) for PTV, CTV, bladder and 
rectum respectively. For complete information of each patient case, see Appendix III.  
 
Figure 4.6 The bar chart presents the differences in absolute doses (presented in %) between sCT/r CT, red bars, and 
CT/rCT, blue bars, for specific organ doses. The evaluation was made for protons. The organs doses are divided into 
14 groups, presented on the x-axis, were each group consists of the result from the sCT/rCT and CT/rCT comparison. 
Each group is presented with its individual standard deviation as error bars (1 s.d.).   
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In Figure 4.7 the gamma evaluation between sCT/rCT and CT/rCT dose distributions is shown for the 
proton treatment planning. The top row presents the sCT/rCT comparison and the bottom row presents 
the CT/rCT comparison. The appearance differs from the IMRT treatment planning in the way that a 
larger zero dose area is present, which in the illustration can be seen as white area surrounding the 
dose distribution.  
 
Figure 4.7 The figure illustrates the gamma analysis in 3D for the proton treatment planning. The isocenter slice from 
the evaluation between sCT/rCT and CT/rCT is shown where the top row presents the sCT/rCT comparison and the 
bottom row shows the CT/rCT comparison. Points with a value ≤ 1 passes the gamma criterion. Beneath each patient 
case, the gamma pass rate is presented in percent, and the mean value is presented below each row of patients. The 
gamma criterion used is 3%/2mm. 
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4.3 Positioning study 
4.3.1 Bone match 
The result from the bone match study is presented in Table 4.1. The displacements arising from the 
positioning against orthogonal MV images is presented in mm for sCT and CT match and the 
difference between these matches are presented.  The displacement is presented in the vertical (Vrt), 
longitudinal (Lng) and lateral (Lat) directions for each patient, matched for one treatment session. The 
difference between sCT and CT displacements for all five patients is presented in three directions, 
where the mean difference in all directions is below 1 mm.  
Table 4.1 The positioning study was performed with bone match for 5 patients for both CT and sCT images, matched 
against two orthogonal MV images from one treatment session. The results are presented in mm displacement, 
achieved when the images were matched in Eclipse offline-review. The displacements are presented in the vertical 
(Vrt), longitudinal (Lng) and lateral (Lat) directions. Differences between the displacement for the CT and sCT image 
match are presented to the right in the three directions in mm.  
    
Displacement sCT  
[mm] 
Displacement CT  
[mm] 
Difference 
(sCT-CT) [mm] 
Patient 1 
Vrt -2.7 -3.4 0.7 
Lng -21.4 -20.9 -0.4 
Lat 16.8 18.0 -1.2 
Patient 2 
Vrt -11.9 -11.7 -0.2 
Lng -3.5 -2.8 -0.7 
Lat 13.0 14.0 -1.0 
Patient 3 
Vrt -6.9 -5.7 -1.2 
Lng 9.2 7.9 1.4 
Lat 0.1 0.1 0.0 
Patient 4 
Vrt -10.4 -10.2 -0.2 
Lng 1.9 1.1 0.8 
Lat 13.5 14.2 -0.7 
Patient 5 
Vrt 12.1 10.8 1.3 
Lng -3.1 -4.1 1.0 
Lat 10.8 11.1 -0.3 
 
The mean differences between the displacement achieved from the sCT and CT bone match were 0.7 
mm in the vertical direction, 0.9 mm in the longitudinal direction and 0.7 mm in the lateral direction.  
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4.3.2 Fiducial marker identification 
The fiducial marker identification was performed independently by six observers, for four patients. 
The result is presented in Table 4.2 as the mean standard deviation in x-, y- and z-direction for each 
marker and patient resulting from the identification of the six observers. One marker identification 
result for patient 2 was excluded due to an incorrect identification by one observer. See Appendix IV 
for complete information of the individual observer identifications, and specific information of the 
standard deviations in respective direction. 
The result showed that the fiducial markers could potentially be identified, but not in its correct 
position in x-, y- and z-direction. The highest standard deviation, in all directions, was 3 mm and the 
confidence level that the observers experienced ranged between 2 and 5 for all patients. For complete 
information of the markers positions for each observer, see Appendix IV and Appendix V.  
Table 4.2 The fiducial marker identification is presented as the mean standard deviation in x, y and z direction for 
each marker and patient. The mean standard deviation is presented in mm deviation of the location of the markers, 
identified by the six observers. The certainty level is presented for the six observers for each patient, from the smallest 
to the highest level chosen.	  
Patient  Marker  Standard deviation (x, y, z) [mm] Confidence level 
  1 0.3   
Patient 1 2 1.1 3-4 
  3 0.2   
  1 0.7   
Patient 2 2 0.1 2-3 
  3 0.6   
  1 0.1   
Patient 3 2 0.1 2-4 
  3 0.5   
  1 3.0   
Patient 4 2 0.2 4-5 
  3 0.5   
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5. Discussion 
5.1 Image evaluation  
The image evaluation consisted of a visualization of the differences in the bony structures of the 
images and a calculation of the Dice similarity index. The differences were expected to be found at the 
bone surfaces, since the generation of the sCT depends on an MRI without strict information of the 
bones positions. When the images were overlaid in MATLAB, differences could be seen although 
these were relatively small. Overall the CT and rCT images agreed better than the sCT and rCT. The 
rCT and CT bone structures are expected to be very similar since it’s merely a registration of the CT to 
the MR, during which the bones did not deform, that differs between the rCT and the CT. The 
registration shows potential patient repositioning between the MRI and the CT. Repositioning effects 
can be expected to occur in the outer body contours and in the bladder and rectum volume, which are 
volumes that easily moves and are hard to reproduce exactly in position. But the bones are relatively 
stable in their positions and therefore expected to be fairly the same between the imaging sessions. 
This assumption is further strengthened by the feet immobilization and knee support used when the 
patients are positioned, enabling reproduction of the bones positions. 
The Statistical Decomposition algorithm generates sCTs with the bones in similar positions as the 
rCT, with small differences in the bone contours and in the connective areas of the bones; as seen in 
Figure 4.1. This is likely an effect of the sCT generation method, which relies upon the MRI and 
therefore a precise CT copy is not likely to be expected. An additional aspect that could influence the 
result is the blurred appearance of the sCT compared to the rCT and CT. This blurring effect arises 
from the sCT generation and is mostly present in areas with large contrasts/HU differences, for 
instance in the proximity between soft tissue and bone. This can be troublesome when a threshold is 
used to segment the bones. The differences presented and calculated in the images are dependent on 
the threshold used to segment the bones in the images, since this decides how much bone to 
incorporate in the bone structures. The DICE similarity index gives an indication of the similarities in 
the images, where a greater agreement can be seen between the CT/rCT compared to the sCT/rCT. 
The DICE index was in general lower for the cranial slices compared to the caudal slices. The cranial 
slices consist of more complex bone structures and also narrower connective areas, where the blurring 
effect can result in absence of bone structures when a threshold is set. This contributes to a lower 
DICE index.  
5.2 Treatment planning 
The treatment planning procedure is an essential part of the radiotherapy chain, and is an important 
step in order to provide safe and accurate treatments. When introducing an MRI only radiotherapy 
chain, the sCT must provide equal treatment plan quality and accuracy as when a CT is used as image 
material. A high accuracy have been shown for RapidArc treatment planning using the SDA method 
for prostate patients (Siversson et al., 2015), and to further test the feasibility of the method, a set of 
IMRT- and proton treatment plans was produced and evaluated.  
As can be seen in Figure 4.2, Figure 4.3 and Figure 4.6, the differences in mean absorbed doses 
between the sCT and the rCT were in general smaller than between the CT and rCT. This indicates 
that the doses calculated by the treatment planning system (TPS) based on sCT and on rCT are in 
better agreement with each other than those calculated based on the CT. Although differences can be 
seen, these are small and for the sCT/rCT comparison the differences were approximately negligible 
when compared to the overall dose accuracy needed in radiotherapy, where literature suggests 2.5-
3.5% (IAEA, 2000, Brahme, 1984, Goitein, 1983, Mijnheer et al., 1987). This shows that 
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uncertainties, in terms of absorbed doses, introduced by treatment planning on sCT generated by the 
SDA method are negligible, and the resulting dose to target and risk organs are practically the same. 
This is independent of the modality used and the same trend can be seen for the IMRT and proton 
plans.   
The differences between the dose distributions are more distinct for the CT/rCT comparison, which 
can be seen both in the DVH- and the gamma analysis. The larger differences between CT and rCT are 
probably an effect of repositioning between MR and CT. This can be seen as uncertainties introduced 
by repositioning between MR and CT in a combined workflow, which is one of the main concerns 
regarding the combined MRI/CT workflow. This is illustrated in Figure 4.4 and Figure 4.5, where the 
bottom row can be seen to have a larger number of non-passing points between the distributions 
evaluated. Differences can mostly be seen in the edges of the distributions, where the effect of the 
repositioning is mostly present.  
The gamma analysis was used to test if the use of sCT images generated from the SDA method 
resulted in any deficiencies in the resulting dose distribution, when compared to rCT. The result 
showed that the dose distributions resulting from the IMRT treatment planning on the sCT and the rCT 
are in very good agreement with each other. When the treatment plan is recalculated on the CT and 
sCT, the dose planning system must take into account the new structures and geometries of the new 
images, which in this study is the sCT and CT, since the original plan was created on the rCT. These 
three images, rCT, sCT and CT, are supposed to be similar, although some disparities are expected to 
be found. The disparities result in various dose distributions, which in a wide perspective is found to 
be very similar. For example are the absorbed doses to the inner structures as PTV, bladder and rectum 
relatively unaffected. At the field edges the differences seems to be of larger extent, which contributes 
to the calculation not passing the gamma evaluation completely at all evaluation points.  
The DVH analysis of the proton plans showed a larger deviation between the rCT and CT plan than 
showed for the IMRT plans. The protons are more sensitive to the position of structures, and the 
differences that can be detected in rectum and bladder volume results in a larger deviation when the 
rCT and CT plans are compared. A larger difference can also be seen in the femoral heads; which also 
is a result of the more sensitive behavior of the protons. However, the sCT/rCT comparison showed, 
regardless of the larger deviation between CT/rCT, a good agreement. The proton gamma analysis 
resulted in lower pass rate than the IMRT evaluation. The gamma criterion was eased in order to 
identify the areas with largest differences in calculation results. The protons more sensitive range 
properties influenced the gamma evaluation, and the pass rate was lower than for the photons. The 
mentioned blurring effect in the image analysis become visible in the gamma analysis, and a streak of 
red non-passing points could be seen in similar positions as where the bone contours differed in the 
image analysis. Regardless of this fact, the proton treatment plan would, according to the clinical 
criteria used in this work, be acceptable.  
In this study, the same structures were used in all datasets. Another option would have been to create 
new structures on each image.  However, this would have required different treatment plans for each 
image which would be a drawback when comparing the calculated dose distributions. The method 
used in the study enables comparison of volumes of the same size and position, but can result in a 
structure volume that does not agree with the CT. The structure outlined on the MR should agree with 
both sCT and rCT, but the CT can be different due to reposition between imaging sessions. This in 
turn enables investigation of the repositioning effects, as shown in the study.  
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5.3 Positioning study 
The aim of the positioning study was to investigate positioning possibilities in an MRI only workflow 
and to detect possible difficulties. The suggested workflow was followed, in which bone match or 
fiducial marker match was the suggested techniques for prostate cancer patients, when considering a 
workflow without the possibility of a matching procedure with MR.   
The bone match was performed with MV images and resulted in a mean difference below 1 mm when 
the CT and sCT match displacements was compared. This result indicates that despite the small bone 
differences that could be seen in the image evaluation, the matching could work in the same manner in 
the MRI only workflow as in the conventional workflow. The differences ranged in mean values 
between 0.7-0.9 mm in all directions, where the smallest deviation was 0.0 mm and the largest 1.4 
mm. The result is dependent on the operator that performs the match, and the operator’s experience is 
important for the continuation in developing positioning strategies. The initial experience from this 
study was that the sCT and CT could be matched in similar ways to the MV images, and no significant 
difference in the matching procedure was detected. The bone match with MV or kV images is not 
always the preferred method for prostate cancer patients. Due to daily variations in prostate placement 
and soft tissue, it is preferred to do either a CBCT or a fiducial marker match to encounter such 
variations. Despite this, the bone match can be preferred for other diagnosis such as head and neck 
cancers where soft tissue movement is a smaller concern. The use of fiducial markers in the prostate 
enables to encounter the daily variations in position of the prostate, and the use of fiducial marker 
match is a modality that needs further consideration in the MRI only workflow.  
The fiducial marker identification study in this thesis aimed to test the concept of the fiducial marker 
positioning strategies that are used in the conventional workflow for prostate patients. Early on it was 
clear that the markers was hard to identify exactly in the LAVA-flex MR images that were available. 
This resulted in an observer study that tested the precision that the markers could be identified with 
and the observers experienced confidence regarding the identification. The study showed that the 
markers in most cases could be identified with good precision, except in one case were a marker was 
identified far off from the correct position. The actual patient case had small air cavities or 
calcifications in the prostate that confused the observers. This resulted in a confidence level between 2 
and 3, which would result in this patient not being passed on to treatment. The misplaced marker was 
identified in the position of an air cavity or calcification that easily could be mistaken for as a marker. 
The main experience from the observers was that the markers were hard to identify, but the task was 
feasible. This is a problem that needs to be addressed, and the use of sequences with better 
identification possibilities is essential for the continuation of fiducial marker positioning in the MRI 
only workflow. Alternative marker materials are also an alternative that could improve the 
identification possibility. Alternative markers have been tested for the conventional workflow 
(Habermehl et al., 2013); the identification feasibility of these markers on an MRI would be an 
interesting study.     
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5.4 Summary 
The parts of the workflow investigated in this thesis are strongly connected. The image evaluation 
hypothesis was that the bone contours were expected to be hard to reproduce in a synthetic CT, which 
to some extent were found to be adequate. The segmented bone structures were not identical between 
the sCT and rCT. This was expected to be translated in to the treatment planning result, were the larger 
attenuation properties of the bones were expected to lead to larger disparities between the sCT and 
rCT dose distributions. This was not the case. Even though differences between sCT and rCT could be 
observed, and calculated with the DICE index, the evaluated DVH points were comparable for the 
plans. This indicates that an exact bone agreement is not necessary for creating comparable dose plans 
for the DVH points evaluated in this work. The DICE index should not be an exclusive measure on 
whether or not a generation method could be integrated in the MRI only workflow. But the DICE 
index could be used to evaluate how different generation methods works and compares, in order to 
detect advantaged and difficulties in generation methods. A good agreement in the bone positions of a 
generated synthetic CT and the original CT is always preferable, but the question is to which extent 
the images must agree in order to create comparable dose distributions? From this study we can see 
that despite disparities in the bone surfaces of the sCT and rCT, the resulting dose distributions were 
comparable to a very high degree. Small differences do not influence the result distinct for the 
photons, but the protons shows a more sensitive behavior to these disparities.    
Positioning strategies in an MRI only workflow is a fairly unexplored area, and from this thesis it can 
be concluded that this part of the workflow needs to be carefully further studied. Focuses of 
researchers has been on creating and developing different generation methods, in order to have an 
operating dose planning foundation. This is an important step towards an MRI only workflow, but in 
order to enable a complete MRI only workflow, more insight in the positioning strategies is needed. 
This study was limited by time and availability of patient material, but the work done indicates an 
interesting future with further investigations on positioning strategies. 
A consistent concern when investigating MRI only is the uncertainties that are introduced by the 
different steps involved in MRI only. This thesis showed that treatment planning on sCT introduced a 
mean dose difference to PTV of -0.1% (6MV), -0.2% (10MV) and -0.1% (protons) when comparing 
sCT and rCT. In the context of overall dose accuracy, the uncertainty contribution from dose planning 
on sCTs generated from the SDA seems negligible. When considering introducing uncertainties, it is 
also important to remember that the MRI only workflow is intended to eliminate uncertainties. 
Nyholm et al. states that the MRI only workflow reduces geometrical uncertainties with 1-2 mm when 
compared to a combined CT/MR workflow for prostate patients (Nyholm et al., 2009). The bone 
positioning study in this work showed a mean difference of 0.7-0.9 mm between sCT and CT bone 
match. If compared to the uncertainties eliminated through exclusion of the co-registration process, 
this additional contribution of uncertainty seems acceptable. The differences between the sCT and CT 
match does not solely depend on that the sCT is synthetic, the rigid registration of the CT and sCT 
influences the result. In the actual study only one observer performed the match, which also influences 
the result.   
The MRI only workflow has many steps that could introduce random and systematic errors, and all of 
them are not possible to handle in this work. Geometrical distortions are a concern that commonly is 
mentioned along with MRI-based radiotherapy as one of the main challenges (Korsholm et al., 2014), 
and are a phenomenon that can influence the clinical outcome of the treatment (Walker et al., 2014). 
The distortions can be caused both by the system used for imaging, but can also be patient dependent. 
Even though this is a common concern in MRI only, there are works describing methods to reduce the 
distortions (Crijns et al., 2011). The possible alternative to the combined MR/CT workflow for 
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prostate patients has its difficulties, but also shows promising results. The MRI only workflow cannot 
completely replace the CT/MR workflow at the present time, but the field is fast developing and the 
technique shows a promising future.  
It is important to understand not only the possibilities but also the concerns with the MRI only 
workflow. The use of smaller margins is often mention as a positive effect of the use of MR, but 
reduced margins can also lead to deficit of dose to PTV if the prostate moves during treatment. A 
possibility of increasing the dose to the target can be possible with decreased margins. OARs can be 
avoided and a high dose to target can be delivered at the same time as side effects are avoided. This 
can be a positive effect but if the patient moves during treatment an unwanted high dose can be 
delivered to an OAR.   
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6. Conclusion  
The dose planning study showed good agreement between the resulting dose distributions arising from 
dose planning on sCT and rCT for all treatment modalities tested (i.e. 6 and 10 MV IMRT and spot 
scanning protons), which indicates that SDA generated sCT images can be used in an MRI only 
workflow. The image evaluation indicated some disparities in the bone surface between sCT and rCT, 
but this had only small effect on the resulting dose distributions for photon plans. The proton plans 
indicated a larger sensitivity on the differences in bone contours. To evaluate the usability of a sCT in 
an MRI only workflow it’s vital to evaluate the outcome of the treatment, and to ensure that the 
prescribed treatment is delivered as when a CT is used. The positioning strategies in the MRI only 
workflow represent a part of the workflow that needs to be further investigated. The initial results of 
this study show a problem with transferring the fiducial marker positioning strategies in the 
conventional workflow to the MRI only workflow. The markers cannot be convincingly identified 
using the sequence investigated. The bone match can be performed and this is a matching procedure 
that likely can be usable in the MRI only workflow.  
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7. Future perspective 
The main limitation in this thesis was the limited time and available patient material. Further work is 
needed in order to incorporate an MRI only workflow in the radiotherapy clinic. This work did only 
investigate one generation method in one anatomical site, which leaves room for further studies with 
larger patient selections and multiple generation methods. The investigation of different generation 
methods can result in improvements in the available methods, but also enable evaluation methods that 
can be used for comparison. The different generation methods focus on different sites and techniques, 
and a fair evaluation method for comparison is needed in order to move further when comparing 
different methods. 
The image analysis implicated interesting findings that could be further investigated. The mentioned 
blurring effect is a possible effect from the SDA generation and further work with the generation 
method can result in possible improvements. An improvement of the images, that already shows 
promising treatment planning results, can result in even better results that could further favor the use 
of MRI in radiotherapy.  
As mentioned in the discussion and conclusion, the MRI only positioning strategies need further 
studies. The desire to find and develop positioning guidelines in the new workflow is an important 
task that demands larger observer groups and an extended patient selection. The bone match study 
would preferably be performed with larger patient selections, with different anatomical sites. In order 
to reduce the influence of the observer, a multiple observer study, as for the marker identification, 
would be interesting. The marker study showed that even though the markers could be identified, the 
observer did not feel confident of the marker positions for all patients. This is an issue that comes in 
early in the chain, and the development of better sequences which leads to more confident marker 
identifications could likely have a positive effect on the whole workflow. Bone match is not always 
the preferred matching procedure for prostate patients, and it can often be desirable to locate soft tissue 
in the matching images. Procedures that enable this would be of interest for investigation, such as 
CBCT match with bones and soft tissue and ultimately a solely soft tissue match with MRI.  
When considering the MRI only workflow, it is important to see the complete workflow from end to 
end and not only focus on individual steps in the workflow. In order to incorporate MRI in 
radiotherapy, the whole chain must be connected and stable in order to reach the ultimate goal – a safe, 
reliable and successful treatment. 
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Appendix I - DVH parameters for IMRT treatment plans.  
6 MV IMRT treatment planning results for each patient case. The result from the DVH comparison 
between the rCT and the CT and sCT, respectively, is shown in the table below. 
 Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 
 CT sCT CT sCT CT sCT CT sCT CT sCT CT sCT 
Body             
Mean N/A -0.3 N/A 0.1 N/A -0.2 N/A -0.1 N/A -0.1 N/A 0.0 
Max 0.7 -0.9 -1.2 0.6 0.2 0.0 -2.2 -1.4 -0.6 -0.4 -0.3 0.3 
PTV             
Mean 1.0 -0.4 -0.8 0.4 -0.3 -0.2 -0.8 -0.3 -0.6 -0.2 -0.1 0.2 
V95% 0.2 -0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
D99% 1.4 -0.3 -0.8 0.2 -0.3 0.1 -0.4 0.1 -0.5 -0.1 -0.2 0.3 
CTV             
Mean 1.1 -0.5 -0.8 0.4 -0.4 -0.1 -1.0 -0.3 -0.6 -0.2 -0.1 0.2 
Min 1.1 -0.7 -0.7 0.2 -0.7 -0.1 -1.1 -0.2 -0.6 -0.1 -0.3 0.5 
Bladder             
Mean -1.2 -0.2 1.4 -0.3 1.2 -0.6 0.2 -0.4 2.0 -0.2 -0.5 0.0 
Rectum             
Mean 1.5 -0.5 1.5 0.3 -0.2 -0.1 0.2 -0.1 1.3 0.0 0.6 0.0 
V90% 10.3 -2.6 0.6 1.6 -1.2 -0.3 -1.1 -0.2 -2.2 -0.4 0.7 -0.1 
V75% 4.5 -1.3 1.5 0.3 0.3 -0.3 0.9 -0.9 -0.1 0.2 0.8 0.0 
V65% 2.9 -0.9 1.8 -0.5 0.8 -0.3 1.6 -0.1 0.8 0.3 0.4 0.0 
Femoral heads             
Mean -0.1 -0.3 -0.9 -0.7 1.0 -0.6 -0.9 -0.2 0.0 -0.1 0.1 0.0 
Max 4.1 -0.3 -0.9 -0.5 -0.1 -0.8 1.0 0.5 -0.8 -0.8 0.0 -0.1 
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Appendix II - DVH parameters for IMRT treatment plans. 
10 MV IMRT treatment planning results for each patient case. The result from the DVH comparison 
between the rCT and the CT and sCT, respectively, is shown in the table below. Results presented in 
percent. 
 Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 
 CT sCT CT sCT CT sCT CT sCT CT sCT CT sCT 
Body             
Mean  N/A -0.4 N/A -0.1 N/A -0.2 N/A -0.1 N/A -0.3 N/A -0.1 
Max 0.8 -0.7 -1.1 0.5 0.0 -0.1 -0.6 0.0 -0.3 -0.1 -0.5 -0.1 
PTV             
Mean  1.0 -0.5 -0.7 0.2 -0.2 -0.2 -0.5 -0.2 -0.5 -0.3 -0.2 0.0 
V95% 0.3 -0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
D99% 1.4 -0.4 -0.7 0.0 -0.1 0.0 -0.2 0.0 -0.4 -0.3 -0.2 0.0 
CTV             
Mean  1.0 -0.5 -0.7 0.2 -0.3 -0.2 -0.6 -0.2 -0.6 -0.3 -0.2 0.0 
Min 1.1 -0.7 -0.6 0.0 -0.2 0.0 -0.7 -0.2 -0.7 -0.3 -0.2 0.1 
Bladder             
Mean  -1.2 -0.3 1.5 -0.4 1.2 -0.7 0.4 -0.3 1.8 -0.3 -0.6 -0.2 
Rectum             
Mean  1.4 -0.6 1.6 -0.2 -0.2 -0.2 0.4 0.0 1.4 -0.1 0.6 -0.1 
V90% 9.6 -2.6 0.0 0.5 -1.3 -0.4 -0.2 -0.3 -1.9 -0.7 0.3 -0.6 
V75% 4.3 -1.1 1.3 -0.8 0.3 -0.4 1.4 -0.1 0.2 0.0 0.4 -0.2 
V65% 2.9 -0.8 3.1 0.0 0.8 -0.4 1.9 -0.1 0.7 0.0 0.2 -0.1 
Femoral heads             
Mean  -1.1 -0.3 -0.7 -0.8 0.7 -0.6 -0.6 -0.1 0.5 0.0 -0.1 0.0 
Max 3.2 -0.5 -0.7 -1.0 1.3 -0.8 0.1 0.7 -1.5 -0.4 -0.2 0.0 
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Appendix III - DVH parameters for proton treatment plans. 
Proton treatment planning results for each patient case. The result from the DVH comparison between 
the rCT and the CT and sCT, respectively, is shown in the table below. Results presented in percent.  
 Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 
 CT sCT CT sCT CT sCT CT sCT CT sCT CT sCT 
Body                         
Mean  N/A 0.1 N/A 0.2 N/A -0.4 N/A -0.4 N/A 0.2 N/A 0.8 
Max 0.0 0.6 -0.1 0.4 0.6 0.7 -0.4 0.8 0.3 0.1 0.6 0.1 
PTV             
Mean  -0.3 -0.1 0.0 -0.2 -0.3 -0.1 -0.7 0.0 -0.1 -0.1 -0.2 -0.4 
V95% -1.7 -0.1 -0.1 -0.2 -0.3 -0.1 -1.6 -0.1 -0.3 -0.2 -0.1 -0.1 
D99% -2.8 -0.6 -0.1 -0.7 -0.7 -0.5 -3.9 -0.4 -0.6 -0.6 -0.7 -0.7 
CTV             
Mean  -0.1 0.0 0.0 0.0 -0.2 0.0 -0.2 0.0 -0.1 0.0 -0.2 -0.2 
Min -0.6 -0.3 -0.4 -0.4 -0.4 -0.4 -0.7 -0.4 -0.1 0.0 -0.8 -0.7 
Bladder             
Mean  15.5 -0.3 -4.0 -0.3 2.5 -0.7 3.5 -0.4 0.5 0.4 0.3 1.0 
Rectum             
Mean  -6.3 -0.1 3.3 -1.3 -1.0 -0.2 -5.5 0.3 2.0 0.1 1.1 -0.4 
V90% -7.8 -1.0 4.0 5.3 -3.6 -0.3 -11.7 2.1 2.4 0.5 -1.3 -1.7 
V75% -6.7 -0.2 3.8 -1.3 -2.0 -0.3 -8.3 0.5 1.3 0.2 0.2 -0.4 
V65% -6.7 0.0 4.0 -0.9 -1.4 -0.3 -7.1 0.2 1.7 0.1 0.6 -0.4 
Femoral heads             
Mean  10.7 0.0 -1.6 0.0 0.4 0.0 4.6 0.1 -0.8 -0.2 -2.0 -0.7 
Max -0.1 -0.6 -0.2 0.2 0.0 0.1 -0.7 0.8 -1.3 -0.3 -1.5 -0.8 
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Appendix IV – Fiducial marker identification observer study results.  
In the table below the results from the fiducial marker identification study are shown for case 1 and 
case 2. The observers are named 1-6 and the markers 1-3 as described in section 3.6.2. The numbers in 
red indicates the marker which was identified wrong, and therefore not included in the standard 
deviation.  
Patient Marker Position 1 2 3 4 5 6 Standard deviation [mm] 
Patient 1 
1 
X 36.5 36.7 36.8 36.6 37.0 36.7 0.2 
Y 79.2 79.2 79.3 79.2 79.2 79.5 0.1 
Z 5.1 5.2 6.1 5.8 6.1 6.2 0.5 
2 
X 0.4 -3.0 -3.1 -3.1 -2.9 -3.2 1.4 
Y 69.2 69.2 69.2 69.2 6.92 68.0 0.5 
Z 5.1 1.8 2.8 2.0 1.7 2.3 1.3 
3 
X 32.2 32.3 32.0 31.6 32.1 32.2 0.3 
Y 69.2 69.2 69.1 69.2 69.2 68.8 0.2 
Z -1.4 -1.2 -1.0 -1.1 -1.3 -1.1 0.1 
Patient 2 
1 
X 8.1 8.6 8.9 7.9 8.5 8.8 0.4 
Y -9.5 -7.0 -7.4 -9.5 -7.0 -7.6 1.2 
Z 16.1 17.1 16.4 17.0 16.1 16.7 0.4 
2 
X -14.0 -14.0 -14.2 -14.0 -13.8 -14.3 0.2 
Y -17.0 -17.0 -16.8 -1.70 -17.0 -17.0 0.1 
Z 9.3 9.3 .93 9.2 9.2 9.1 0.1 
3 
X 7.4 7.8 7.1 6.9 1.5 7.4 0.3 
Y -12.0 -12.0 -12.1 -14.5 3.0 -12.0 1.1 
Z 2.2 2.3 2.4 3.1 23.7 2.4 0.4 
 
  
42	  
	  
Appendix V - Fiducial marker identification observer study results. 
In the table below the results from the fiducial marker identification study are shown for case 3 and 
case 4. The observers are named 1-6 and the markers 1-3 as described in section 3.6.2.  
Patient Marker Position  1 2 3 4 5 6 Standard deviation [mm]  
Patient 3 
1 
X 25.8 25.8 25.8 26.4 25.8 25.8 0.2 
Y 16.9 16.9 16.9 16.9 16.9 16.9 0.0 
Z 0.0 0.3 0.5 0.4 0.4 0.4 0.2 
2 
X -6.3 -6.0 -6.3 -6.3 -6.3 -6.3 0.1 
Y 6.9 6.9 6.9 6.9 6.9 6.9 0.0 
Z 0.8 0.0 0.4 0.6 0.4 0.4 0.3 
3 
X 1.3 1.3 1.6 1.7 1.7 1.6 0.2 
Y 1.9 1.9 2.8 4.4 1.9 3.4 1.0 
Z -3.2 -2.9 -3.0 -3.6 -2.7 -3.1 0.3 
Patient 4 
1 
X -1.0 -1.6 -1.8 -1.5 -1.4 -1.1 0.3 
Y 22.6 22.6 21.6 22.6 22.6 22.6 0.4 
Z 55.7 34.9 35.5 35.2 35.0 35.6 8.4 
2 
X -23.3 -23.0 -22.9 -23.2 -23.3 -23.1 0.2 
Y 27.6 27.6 27.3 27.6 27.6 27.1 0.2 
Z 36.6 36.2 36.5 36.5 36.4 36.9 0.2 
3 
X -5.5 -5.9 -6.0 -6.1 -5.9 -6.1 0.2 
Y 17.6 17.6 18.7 17.6 17.6 19.5 0.8 
Z 37.9 38.8 38.4 38.3 37.7 38.2 0.4 
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Appendix VI – DICE calculation  
In the table below the DICE calculation for patient case 1-3 are shown. The calculations are done in 20 
slices and the mean value of these presented at the bottom of each row. The DICE value is in percent. 
 
Case 1 Case 2 Case 3 
Slice sCT CT sCT CT sCT CT 
20 86.9 93.1 84.6 93.3 91.3 92.7 
21 86.7 93.4 85.4 94.4 91.0 93.7 
22 87.5 92.3 85.6 94.1 90.7 92.8 
23 87.1 93.7 85.5 93.2 89.8 91.3 
24 86.2 93.4 85.0 93.4 89.5 89.0 
25 86.5 93.1 85.6 93.0 89.1 91.3 
26 86.3 93.7 86.1 91.3 89.4 89.8 
27 85.9 92.4 86.1 91.6 88.6 87.7 
28 85.7 92.9 86.0 92.2 87.5 90.2 
29 87.2 93.9 85.7 90.5 88.1 88.7 
30 86.5 91.8 85.3 89.8 86.4 91.1 
31 86.1 93.3 86.2 91.8 83.3 92.3 
32 82.7 91.7 85.2 91.4 86.3 92.6 
33 81.3 89.3 84.8 92.2 91.1 92.4 
34 81.8 89.4 87.1 93.1 89.8 92.9 
35 83.0 87.7 86.4 91.1 87.0 90.5 
36 82.7 84.4 85.8 90.3 88.1 88.8 
37 85.4 91.5 84.7 90.6 86.9 88.0 
38 84.4 92.9 82.6 89.9 86.1 88.1 
39 84.9 86.3 83.5 90.6 87.9 90.3 
40 88.6 93.6 81.8 89.7 87.9 89.6 
Mean 85.4 91.6 85.2 91.8 88.4 90.7 
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Appendix VII – DICE calculation 
In the table below the DICE calculation for patient case 4-6 are shown. The calculations are done in 20 
slices and the mean value of these presented at the bottom of each row. The DICE value is in percent.  
 
Case 4 Case 5 Case 6 
Slice sCT CT sCT CT sCT CT 
20 88.6 96.2 89.6 96.0 90.4 94.3 
21 88.9 95.2 89.5 94.8 89.8 93.8 
22 89.0 96.2 89.9 95.6 89.6 93.6 
23 88.5 96.2 89.8 95.4 89.6 93.1 
24 88.8 95.4 90.7 95.0 90.0 93.0 
25 89.3 95.8 91.3 95.7 90.6 93.9 
26 89.7 95.8 91.1 95.8 90.9 94.6 
27 89.6 95.4 90.7 95.4 91.1 93.2 
28 89.7 93.6 90.7 95.6 90.9 94.3 
29 89.2 95.3 90.7 95.4 90.3 94.4 
30 89.0 94.8 90.0 94.3 90.2 93.1 
31 88.8 93.1 89.6 95.8 90.2 93.7 
32 88.3 94.5 88.4 93.7 87.7 95.6 
33 87.3 93.1 88.9 93.4 90.3 95.1 
34 85.8 92.6 89.9 95.9 92.4 95.0 
35 84.6 88.1 89.5 94.6 91.6 96.0 
36 84.1 86.8 89.2 93.4 91.1 94.7 
37 89.0 94.2 88.8 95.0 89.5 94.4 
38 88.4 94.5 88.2 94.4 87.8 95.1 
39 88.7 89.6 85.0 92.9 89.5 92.7 
40 83.2 86.4 85.1 93.8 89.3 95.0 
Mean 88.0 93.5 89.4 94.8 90.1 94.2 
	  
